HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Indoco Remedies rises on getting EIR from USFDA for API manufacturing facility at Patalganga
Dec-12-2025

Indoco Remedies is currently trading at Rs. 241.05, up by 1.65 points or 0.69% from its previous closing of Rs. 239.40 on the BSE.

The scrip opened at Rs. 240.00 and has touched a high and low of Rs. 251.05 and Rs. 239.25 respectively. So far 1433 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 348.60 on 17-Dec-2024 and a 52 week low of Rs. 190.00 on 28-Feb-2025.

Last one week high and low of the scrip stood at Rs. 254.70 and Rs. 236.05 respectively. The current market cap of the company is Rs. 2223.64 crore.

The promoters holding in the company stood at 58.90%, while Institutions and Non-Institutions held 19.41% and 21.69% respectively.

Indoco Remedies has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga, following a successful Inspection of the said facility from September 15, 2025 to September 19, 2025.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

  RELATED NEWS >>